Rational combination therapies for JAK-driven haematological malignancies

Project Description

Our research focuses on novel combination therapies for haematological cancers driven by activation of particular cell survival pathways. We investigate how certain genetic changes promote the survival of cancer cells, and how these cancer cells become resistant to drug treatment. This will allow us to develop novel potent combination therapies for the treatment of acute leukaemia and myeloproliferative neoplasms, and to overcome drug-resistance to improve the outcomes for patients.

Lay report

Year

2015-2017

Researchers

Dr Michaela Waibel, Prof Ricky Johnstone, Prof John Seymour

Funding Body

Cancer Council Research Grant

Institution

Cancer Therapeutics Program, Peter MacCallum Cancer Centre

Funding

$99,805 per annum

Updated: